The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting

• Status: Active, not recruiting
• Trial end date: 2023-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the efficacy of Aprepitant + standard antiemetic regimen in reducing postoperative nausea and vomiting after laparoscopic gastric sleeve versus placebo + standard antiemetic regimen

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital General Tlahuac
• Treatments: Aprepitant

Criteria

Inclusion Criteria:

• 18 to 65 years old.

• Non-smokers.

• Obesity with BMI > 30 kg/m2.

• Undergoing laparoscopic gastric sleeve.

Exclusion Criteria:

• Documented hypersensitivity to any component of the study regimen.

• Current treatment with: Orap (pimozide), Seldane (terfenadine), Hismanal (astemizole) or Propulsid (cisapride).

• Allergy to opioid drugs used in the anesthetic protocol.

• Drug or alcohol abuse.

• Chronic nausea and vomiting.

• Previous bariatric procedures.